An observational study in Multiple Myeloma (MM) and Hematologic Neoplasm, sponsored by Azienda USL Reggio Emilia - IRCCS. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Azienda USL Reggio Emilia - IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Multiple Myeloma with a site in Italy — 56 open to participants now, 98 under way, 43 of them phase 3. Multiple Myeloma · Italy.
Among the 286 studies in Multiple Myeloma with a site in Italy, this one is the 26th largest by enrollment of the 56 observational ones that give a count, is one of 15 that started in 2025, is one of 57 observational ones, reaches primary completion later than 24 of the 97 other live ones, and was the 263rd registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →56 of the 286 studies in Multiple Myeloma with a site in Italy are open now. Recruiting first, the newest first:
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18–75 · Healthy volunteers
AstraZeneca · Sites in Italy, United States, Australia and 15 more countries
Ages 18–130
CSL Behring · Sites in Italy, United States, Belgium and 8 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Italy, Australia, Czechia and 11 more countries
Ages 18+
AstraZeneca · Sites in Italy, United States, Australia and 12 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 96 · Phase 3 95 · Phase 4 1
First in 1997; this study’s year is marked. 15 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 208 is above the median of 150 across 486 observational studies indexed under Multiple Myeloma.
Median enrollment 168 across the 227 interventional studies, 200 across the 56 observational. Of the 173 that completed or were terminated, 69 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
161 of 286 have an industry lead sponsor. The 10 most frequent:
Azienda USL Reggio Emilia - IRCCS is the lead sponsor of 93 studies on the registry; 24 are open to participants now.
Azienda USL Reggio Emilia - IRCCS has 4 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
23 of the studies in Multiple Myeloma with a site in Italy that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05455320Phase 3Janssen Research & Development, LLCA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | 2027-07-30 |
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
Add all 23 to your calendar (.ics) → With an account.
Among the 286 studies in Multiple Myeloma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Individuals with multiple myeloma (MM) are vulnerable because of the effects of systemic organ damage and the side effects of treatment. A decline in patients' health-related quality of life (HRQoL) and a compromised participation in everyday life was reported. The diagnosis of MM negatively affects the principal informal caregiver. This is a concurrent exploratory mixed methods study that involves the use of a quantitative and a qualitative approach. For the quantitative study, aims are to describe any possible relation between the identified factors with HRQoL and participation in individuals with MM and with reactions to caring and self-efficacy of caregivers. For the qualitative study, aims are to investigate "how" and "why" the disease impacts the daily life of individuals with MM and their caregivers. The final analyses will be based on the comparison of the results of the quantitative phase and the results of the qualitative phase.
MM is a hematological disease caused by an uncontrolled proliferation of plasma cells. Individuals with MM are vulnerable because of the effects of systemic organ damage and the side effects of treatment. A decline in patients' functional status, the deterioration of health-related quality of life (HRQoL) and a compromised participation in everyday life was reported. Moreover, the diagnosis of MM occurs within the context of a family and it negatively affects the principal informal caregiver.
According to the International Classification of Functioning, Disability and Health, participation in daily life plays a key role in rehabilitation as it confers a sense of normalcy to life. Comprehensive rehabilitation intervention aiming at improving HRQoL and facilitating participation has never been implemented with this aim.
From previous systematic reviews, it emerges that patient reported outcomes (PRO) of individuals with MM have been studied mainly in randomized clinical trials, but also few observational studies have been published, conducting also in Italy. In the province of Reggio Emilia, population-based data concerning the HRQoL of individuals with MM have never been collected, as well as for their caregivers. Needs related to participation in everyday life of individuals with MM and their caregivers were mainly studied through qualitative approach.
Although qualitative data are essential in describing a phenomenon, it is currently not possible to quantify the degree of loss of participation in everyday life or to identify patients most at risk of social isolation. As a counterpart, qualitative approach may explain those situations that quantitative approach cannot verify (e.g., reasons behind conditions of social vulnerability). For these reasons, it seems appropriate to explore the patients' perceived HRQoL and participation from both quantitative and qualitative perspectives, as well as the caregivers' burden, by integrating these data. In this study, needs and difficulties in accomplishing the relevant activities and roles as well as the description of factors that act as facilitators or barriers to HRQoL and participation will be identified to screen patients that might benefit most from rehabilitation. Based on these data, comprehensive and tailored rehabilitation may be planned in future studies and tested for its impact on HRQoL and participation.
This is a concurrent exploratory mixed methods study that involves the use of a quantitative and a qualitative approach. The quantitative is the main study, while the qualitative is the sub-study. Participants of the qualitative study will be a sub-group of those recruited in the quantitative study. In this mixed methods study, we will recruit individuals with MM and caregivers.
For the quantitative study, aims are to describe any possible relation between the identified factors with HRQoL and participation in individuals with MM and with reactions to caring and self-efficacy of caregivers. Data collection will be performed through an individual semi-structured interview conducted in person, remotely or through self-administration, based on participant preference and availability.
As for individuals with MM, the semi-structured interview will consist in the collection of sociodemographic and work-related characteristics, while the side effects of treatments, the needs perceived from this population and the outcomes of interest will be collected through validated assessment tools. Disease-related factors will be retrieved from medical records.
As for caregivers, the semi-structured interview will consist in the collection of sociodemographic and work-related characteristics, while the outcomes of interest will be collected through validated assessment tools. The analyses of the quantitative phase will be carried out at the end of the quantitative data collection.
Qualitative Sub-Study To complement the findings of the primary quantitative study, a qualitative sub-study will be conducted to deepen the understanding of the disease-related experiences of individuals with MM and their informal caregivers and its consequences on daily life.
This qualitative sub-study is embedded within the larger concurrent exploratory mixed methods design. Participants in the qualitative phase will be a purposeful sub-sample of those already enrolled in the quantitative study, selected to ensure variation in the line of therapy (LOT), gender, and occupational status. Inclusion will aim to represent diverse patient and caregiver experiences.
In this qualitative sub-study, open-ended questions will be asked to participants by using interview guides, one for individual with MM and one for caregiver. Before conducting the qualitative interviews, a preliminary phase will be organized where researchers will involve expert patients and caregivers to support them in defining themes and questions of the interview guide. As an example, questions of the final interview guide will be: "Could you describe your life experience and your health after being diagnosed with multiple myeloma? How do the symptoms and the disease affect your daily life? What does caring for your loved one mean to you?".
Data will be collected through semi-structured interviews conducted in person or via video call, based on participant preference and availability. All interviews will be audio-recorded, transcribed verbatim, and analyzed through the reflexive thematic analysis using an inductive approach associated to open coding. Analysis will be iterative and involve multiple researchers to ensure inter-rater reliability of the coding procedure and the methodological rigor of the analysis.
The qualitative phase analyses will be carried out at the end of each interview because, based on the themes that will emerge from each interview, we will understand when to stop recruiting.
The final analyses of the mixed methods study will be based on the comparison of the results of the quantitative phase and the results of the qualitative phase. The comparison will be performed using data triangulation or other methods depending on the level of agreement of results of both phases. From the comparison we would like to understand to what extent the results of the qualitative study confirm those of the quantitative study or if the themes that we will develop from the qualitative interviews will show other issues. This merging of the results will allow us to define a set of criteria to identify those individuals with MM and caregivers in need of support and who could benefit more from a tailored rehabilitation intervention.
The study population consists of adult individuals diagnosed with MM who are receiving treatment at the Hematology Unit of the Azienda USL-IRCCS of Reggio Emilia, and their primary informal caregivers. This population reflects a real-world clinical context, including patients at different lines of therapy (LOT I, II, or ≥III) and with diverse sociodemographic and clinical backgrounds.
Inclusion criteria for individuals with MM will be:
Exclusion Criteria:
Comorbidities that limit collaboration (e.g., dementia, severe psychiatric disorders).
_________________________________________________________________
Inclusion criteria for caregiver will be:
This cohort includes individuals diagnosed with multiple myeloma and receiving treatment at the Hematology Unit of the Azienda USL-IRCCS di Reggio Emilia. The cohort will reflect a real-world clinical population, including individuals across different treatment lines and sociodemographic backgrounds. Patients with severe cognitive or psychiatric comorbidities that prevent active participation (e.g., dementia, severe mental illness) will be excluded.
This cohort will include informal (unpaid) primary caregivers of individuals with multiple myeloma who are participating in the study. For each eligible patient, we will ask if there is a caregiver-identified by the patient-available and willing to participate. Informal caregivers may include family members, relatives, or close companions who provide regular, unpaid care and support. If no caregiver is available or willing to participate, the patient may still take part in the study; however, caregivers cannot be enrolled independently of the patient.
Health related quality of life (HRQoL)
HRQoL in individuals with MM measured by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 (Quality of Life Questionnaire - Core 30). The QLQ-C30 is composed of three subscales: global health status (two items), functional scales (15 items), symptom scale/ individual items (13 items). Each item is assigned a score between 1 and 4 (4-point Likert scale), excluding items n. 29 and n. 30 (7-point Likert scale). All the subscales and single-item measures range in score from 0 to 100. The higher the score for the global health status, the better the quality of life. The higher the score for the functional scale, the higher the level of functioning. Instead, the higher the score for symptom scale/items, the worse the symptoms.
Time frame: 24 months
Health related quality of life (HRQoL)
HRQoL in individuals with MM measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Multiple Myeloma Module (EORTC) QLQ-MY20. The QLQ-MY20 consists of two subscales on disease symptoms (6 items) and side-effect of treatment (10 items), one functional scale on future perspective (3 items), and one single item on body image. All the subscales and single-item measures of the QLQ-MY20 range in score from 0 to 100. A higher score for disease symptoms and side-effects of treatment indicated worse outcomes, while a higher score in the body image and future perspective indicated better outcomes.
Time frame: 24 months
Participation
Participation in individuals with MM measured by the World Health Organization Disability Assessment Schedule (WHODAS 2.0). WHODAS 2.0 captures the level of functioning in six domains of life: cognition (6 items), mobility (5 items), self-care (4 items), getting along (5 items), life activities (8 items), participation (8 items). Each item of the WHODAS 2.0 is assigned a score between 1 and 5 (5-point Likert scale). The higher the score, the higher the level of disability.
Time frame: 24 months
Reactions to caring
Reactions to caring in caregivers of individuals with MM measured by the Caregiver Reaction Assessment scale (CRA). The CRA is composed of 24 items categorized in 5 subscales: impact on schedule (5 items), impact on finances (3 items), lack of family support (5 items), impact on health (4 items) and caregiver esteem (7 items). Each item is assigned a score between 1 and 5 (5-point Likert scale). The higher the score for the impact on schedule, impact on finances, lack of family support, and impact on health domains, the more the negative impact of caregiving activity, while a higher score in the caregiver esteem domain indicated more positive impact of caregiving activity.
Time frame: 24 months
5. Self-efficacy
Self-efficacy in caregivers of individuals with MM measured by the Caregiver Inventory (CGI-I). It is composed of 21 items categorized in four subscales: managing medical information (3 items), caring for the care recipient (7 items), caring for oneself (5 items), managing difficult interactions/emotions (6 items). Each item is assigned a score between 1 and 9 (9-point Likert scale). Higher scores indicate greater self-efficacy for caregiving.
Time frame: 24 months
Open-ended questions of a semi-structured interview that was written by researchers and clinicians and with the support of expert individuals with MM and their caregivers to collect the disease-related experiences and its consequences on daily life
Themes describing the disease-related experiences and its consequences on daily life of individuals with MM and their caregivers generated through the listening of their narratives
Time frame: 24 months
Plan to share: No
Ran from Jun 2025 to primary completion in Dec 2025, 5 months.
Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 31. This study's 5 months is below that.
Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Dec 2025, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda USL Reggio Emilia - IRCCS